Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Japanese Journal of Clinical Oncology

Volumn 37, Issue 7, 2007, Pages 477-481

  Zenda, Sadamoto ^a,b   Onozawa, Yusuke ^a   Boku, Narikazu ^a   Iida, Yoshiyuki ^a   Ebihara, Mitsuru ^a   Onitsuka, Tetsuro ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Docetaxel; Head and neck; Platinum refractory; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; NEDAPLATIN; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HEMOGLOBINOPATHY; HUMAN; LEUKOPENIA; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; RECURRENT CANCER; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG TOLERANCE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PLATINUM; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 34548369637     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym059     Document Type: Article

References (26)

1. Stewart BW, Kleihues PE. World Cancer Report. Lyon, France, International Agency for Research on Cancer Press 2003.
2. Kotwell C, Sako K, Zack MS, Rao U, Bakamjian V, Shedd DD. Metastatic pattern in squamous cell cancer of the head and neck. Am J Surg 1987;154:439-42.
3. Zbaeren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otalaryngol Head Neck Surg 1987;113:762-4.
4. Seiwert TY, Colen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92:1341-8.
5. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
7. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
8. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
9. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Head Neck 2005;27:843-50.
10. Cohen EE, Lingen MW, Vokes EE, The expanding role of systemic in head and neck cancer. J Clin Oncol 2004;22:1743-52.
11. Leon X, Hitt R, Constenia M, Rocca A, Stupp R, Bestit I, et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R & M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc Am Soc Clin Oncol 2003;21:502 (abstr 2202).
12. Leon X, Hitt R, Constenla M, Rocca A, Stupp R, Kovacs AF, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17:418-24.
13. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
14. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryouho 1999;26:107-16.
15. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000;87:881-6.
16. Kaplan EL, Meire P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
17. Union Internationale Contre le cancer TNM classication of malignant tumors, 6th edn. New York: Wiley-Liss 2002.
18. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.
19. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-7.
20. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-8.
21. Couteau C, Couaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999;81:457-62.
22. Fujii H, Sasaki Y, Ebihara S, Innyama Y, Kida Y, Ichikawa G, Komiyama S, et al. An early phase II study of docetaxel (taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 1995;14:298 (abstr 859).
23. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, et al. Phase I/ II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:107-12.
24. Suzuki M, Nishimura Y, Nakamatsu K, Kanamori S, Koike R, Kawamoto M, et al. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 2003;33:297-301.
25. Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 2006;106:106-11.
26. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071-6.